Capella

Capella—the Online Voice of Progress in RNAi

Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.

New results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, when added to standard of care antihypertensive medications, were presented at the 33rd European Meeting on Hypertension and Cardiovascular Protection. Additional details were presented on the KARDIA-3 study design with zilebesiran as an add-on therapy in patients with high cardiovascular risk and hypertension inadequately controlled by standard of care antihypertensives.

Saxena, et al. “Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study”

Havasi, et al. “Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensive”

New results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term outcomes in patients with acute hepatic porphyria who were not attack-free after the first six months of GIVLAARI® (givosiran) treatment were presented at the European Association for the Study of the Liver (EASL) Congress 2024.

Ventura, et al. “Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study”

New 54-month results from the Phase 2 open-label extension study evaluating long-term treatment with OXLUMO® (lumasiran) in patients with primary hyperoxaluria type 1 were presented at the 61st European Renal Association (ERA) Congress.

Frishberg, et al. “Long-term Treatment with Lumasiran: Final Results from the Phase 2 Open-Label Extension Study”

A new subgroup analysis from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, was presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session.

Saxena, et al. “Consistent Antihypertensive Efficacy of the RNA Interference Therapeutic Zilebesiran: Subgroup Results from the KARDIA-1 Phase 2 Study in Patients with Hypertension”

Results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, when added to standard of care antihypertensive medications, were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session.

Bakris, et al. “Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 KARDIA-2 Study”

New results from a post-hoc analysis of outpatient heart failure worsening in the APOLLO-B Phase 3 study of patisiran were presented at the 2024 ACC Annual Scientific Session. Additional data were also presented from a meta-regression analysis of the association between change in 6-minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy.

Fontana, et al. “Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the APOLLO-B Trial”
Kumar, et al. “Meta-Regression Analysis of the Association Between Change in Six Minute Walk Distance and Survival in Transthyretin-Mediated Amyloidosis With Cardiomyopathy”

Non-clinical data for APP-targeting siRNA showing reduced beta-CTF and corrected endosomal abnormalities in cell models of Alzheimer’s Disease were presented at AD/PD 2024, in Lisbon, Portugal.

Dang, et al. “An RNAi Therapeutic Targeting APP Reduced Beta-CTF and Corrected Endosomal Abnormalities in Multiple Human Alzheimer’s Disease iPSC Lines”

New preclinical data for ALN-HTT02—an RNAi therapeutic development candidate targeting huntingtin (HTT) for Huntington’s disease (HD)—were presented during the CHDI Foundation’s 19th Annual Huntington’s Disease Therapeutics Conference in Palm Springs, CA . Additional data were presented on the emerging tolerability profile of the underlying C16-siRNA central nervous system delivery platform, highlighting potential differences with antisense oligonucleotides (ASOs) in development for HD.

Cantley, et al. “A New Approach to HTT-Lowering Using C16-siRNA Conjugates”
De Angelis, et al. “Emerging Tolerability Profiles of C16-siRNA Conjugates for CNS Delivery”

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.